scispace - formally typeset
Search or ask a question

Showing papers by "John Q. Trojanowski published in 1993"


Journal ArticleDOI
01 Jun 1993-Neuron
TL;DR: It is demonstrated that native A68 does not bind to microtubules (MTs), yet dephosphorylated A68 regains the ability to bind to MTs, and phosphorylation of Ser396 may destabilize MTs in AD, resulting in the degeneration of affected cells.

846 citations


Journal ArticleDOI
TL;DR: It is shown here that Ser-202 (in the numbering of the longest human brain tau isoform) is a phosphorylation site that distinguishes fetal from adult tau and it is identified as one of the abnormal phosphorylated sites in Alzheimer disease.
Abstract: Tau is a neuronal phosphoprotein whose expression is developmentally regulated. A single tau isoform is expressed in fetal human brain but six isoforms are expressed in adult brain, with the fetal isoform corresponding to the shortest of the adult isoforms. Phosphorylation of tau is also developmentally regulated, as fetal tau is phosphorylated at more sites than adult tau. In Alzheimer disease, the six adult tau isoforms become abnormally phosphorylated and form the paired helical filament, the major fibrous component of the characteristic neurofibrillary lesions. We show here that Ser-202 (in the numbering of the longest human brain tau isoform) is a phosphorylation site that distinguishes fetal from adult tau and we identify it as one of the abnormal phosphorylation sites in Alzheimer disease. The abnormal phosphorylation of tau at Ser-202 in Alzheimer disease thus recapitulates normal phosphorylation during development.

457 citations



Journal ArticleDOI
TL;DR: This work demonstrates the intracellular production of beta/A4 peptide and suggests that cultured NT2N cells may provide a unique model system for understanding the contribution of neurons and APP695 to amyloidogenesis in the AD brain.
Abstract: The beta-amyloid or beta/A4 peptides that accumulate as filamentous aggregates in the extracellular space of Alzheimer disease (AD) brains are derived from one or more alternatively spliced amyloid precursor proteins (APPs). The more abundant APPs in the central nervous system are the 695-(APP695), 751- (APP751), and 770- (APP770) amino acid isoforms, and each could be the source of beta/A4 peptide that accumulates in the AD brain. It is plausible that altered metabolism of these APPs by central nervous system neurons could lead to the release and deposition of beta/A4 peptide in brain parenchyma. Thus, we examined the expression and processing of the three major brain APPs in nearly pure human neurons (NT2N cells) derived from a teratocarcinoma cell line (NTera2/c1.D1 or NT2 cells) after retinoic acid treatment. NT2N neurons expressed almost exclusively APP695, whereas NT2 cells expressed predominantly APP751/770. Furthermore, the processing of the APPs in NT2N cells was distinct from NT2 and nonneuronal cells. Most significantly, the NT2N neurons but not the NT2 cells constitutively generated intracellular beta/A4 peptide and released it into the culture medium. This work demonstrates the intracellular production of beta/A4 peptide and suggests that cultured NT2N cells may provide a unique model system for understanding the contribution of neurons and APP695 to amyloidogenesis in the AD brain.

235 citations


Journal ArticleDOI
TL;DR: Evidence that normal adult human tau is abnormally phosphorylated and converted into the subunits of AD paired helical filaments (PHFs) and Lewy bodies (LBs) represent accumulation of altered neurofilament (NF) triplet subunits is reviewed.
Abstract: The neuronal cytoskeleton is one of the most profoundly altered organelles in late life neurodegenerative disorders that are characterized by progressive impairments in cognitive abilities. The elucidation of the protein building blocks of these organelles as well as advances in understanding how these proteins become altered in Alzheimer's disease (AD) and other less common dementing illnesses, i.e., diffuse Lewy body disease (DLBD) or the Lewy body variant of AD (LBVAD), will provide insights into the molecular basis of these disorders. Within, we review evidence that normal adult human tau is abnormally phosphorylated and converted into the subunits of AD paired helical filaments (PHFs), and that Lewy bodies (LBs) represent accumulation of altered neurofilament (NF) triplet subunits. Although the precise biological consequences of PHF and LB formation in neurons is unknown, growing evidence suggests that the formation of PHFs and LBs from normal neuronal cytoskeletal proteins could have deleterious effects on neuronal function and survival. Finally, insights into the composition of PHFs and LBs could lead to the development of novel strategies for the timely and accurate diagnosis of AD, DLBD and the LBVAD.

225 citations


Journal ArticleDOI
TL;DR: It is concluded that transplanted NT2N cells represent a highly advantageous model system for studies of the developmental biology of neurons and their ability to establish molecular and structural polarity.

124 citations


Journal ArticleDOI
TL;DR: It is shown here that a monoclonal antibody to MAP kinases recognizes ERK2 in normal and AD cortex, but ERK1 levels are slightly reduced in the AD brain.

91 citations


Journal ArticleDOI
TL;DR: It is demonstrated that many of the epitopes present in the dystrophic neurites of AD are expressed early in the developing spinal cord and are later extinguished, including adult tau epitopespresent in the brain.

76 citations


Journal ArticleDOI
TL;DR: The distinct molecular programs of lineage commitment in cerebellar progenitor cells and in differentiating neurons and astrocytes of the human cerebellum are described.
Abstract: In order to gain a more complete understanding of the sequential pattern of gene expression during neurogenesis and gliogenesis in humans, we followed the expression of well-characterized, developmentally regulated polypeptides in the cerebellar cortex and dentate nucleus by immunohistochemistry using monoclonal antibodies of highly defined specificity. At 8–10 weeks gestational age (GA), progenitor cells and their immediate progeny in the rhombencephalic ventricular zone expressed vimentin and nestin and, to a lesser extent, microtubule-associated protein 5 (MAP5) and glial fibrillary acidic protein (GFAP), but not the low affinity nerve growth factor receptor (NGFR). In contrast, postmitotic, migrating immature neurons in the intermediate zone gave strong reactions for MAP2, tau, and a nonphosphorylated form of middle molecular weight neurofilament (NF) protein (NF-M) and weak reactivity for NGFR. At 15 weeks GA, proliferating cells of the superficial part of the cerebellar external granular layer stained only for NGFR, while more deeply situated cells of the external granular layer stained positively for NGFR, MAP2, MAP5, tau, and chromogranin A, which correlates with the early outgrowth of parallel fibers. All phosphoisoforms of NF-M as well as the low (NF-L) and high (NF-H) molecular weight NF proteins and alpha-internexin were expressed in the somatodendritic domain of Purkinje cells and dentate nucleus neurons from about 20 weeks GA with a gradual compartmentalization of highly phosphorylated forms of NF-M and NF-H into axons by the end of gestation. Alpha-internexin was also expressed strongly in axons of the deep white matter from 20 weeks GA to adulthood. MAP2, synaptophysin, and NGFR showed early, transient expression in the somatodendritic domain of Purkinje cells followed by the appearance of a 220 kDa nestin-like peptide that continued to be expressed in adult Purkinje cells. Notably, developing dentate nucleus neurons expressed many of these proteins in a similar temporal sequence. Early in the developing cerebellar cortex, the expression of NF protein and synaptophysin occurred in discrete patches or columns similar to those described for other antigens (i.e., zebrins). Finally, radial glia were positive for vimentin, GFAP, and nestin from 8 weeks GA to 8 months postnatal. This study describes the distinct molecular programs of lineage commitment in cerebellar progenitor cells and in differentiating neurons and astrocytes of the human cerebellum. The acquisition of a mature molecular neuronal phenotype correlates with the establishment of structural polarity in cerebellar neurons. © 1993 Wiley-Liss, Inc.

75 citations


Journal ArticleDOI
TL;DR: The results suggest that the formation of neurofilament‐rich Lewy bodies in substantia nigra pars compacta neurons is associated with reduced levels of the heavy and light neurofilaments mRNAs in Parkinson's disease.
Abstract: Lewy bodies are filamentous neuronal inclusions characteristic of Parkinson's disease, and neurofilament triplet proteins are the major components of the filaments in Lewy bodies. Since the neurofilament proteins found in Lewy bodies are abnormally phosphorylated and partially degraded, the formation of Lewy bodies may be due to the defective metabolism of these proteins, and this could lead to impairments in the structure and function of neurofilament rich neuronal processes (i.e., large caliber axons). To gain further insights into the metabolism of neurofilaments in Parkinson's disease, we evaluated neurofilament mRNA levels by semiquantitative in situ hybridization histochemistry in postmorten tissues from Parkinson's disease and control subjects. Substantia nigra pars compacta neurons were examined with digoxigenin-UTP labeled cRNA probes to the heavy and light neurofilament mRNAs. The relative abundance of these mRNAs was measured by videodensitometric image analysis of chromogenic reaction product. Using this approach, we demonstrated that the levels of both heavy and light neurofilament mRNAs were reduced in Parkinson's disease substantia nigra pars compacta neurons. Additionally, the levels of heavy neurofilament mRNA were lowest in Lewy body containing neurons in the Parkinson's disease cases. These results suggest that the formation of neurofilament-rich Lewy bodies in substantia nigra pars compacta neurons is associated with reduced levels of the heavy and light neurofilament mRNAs in Parkinson's disease. Thus, it is possible that the accumulation of abnormal neurofilament proteins in Lewy bodies and diminished neurofilament mRNAs contribute to the degeneration of substantia nigra pars compacta neurons in Parkinson's disease. © 1993 Wiley-Liss, Inc.

71 citations


Journal ArticleDOI
TL;DR: The results indicate that A68 is a component of NFT in this family as it is in Alzheimer's disease, and suggest that post-translational modifications of tau leading to formation of A68 are not unique to Alzheimer’s disease.

Journal ArticleDOI
TL;DR: It is suggested that A68 may interact with beta A4, ubiquitin, and ACT in neuronal perikarya as well as in the extracellular space after release of A68 from degenerating neurons.
Abstract: Aberrantly phosphorylated tau proteins (i.e., A68 or PHF-tau) and beta-amyloid or A4 (beta A4) peptides are major components of pathologic lesions in Alzheimer disease (AD). Although A68 and beta A4 colocalize in AD neurofibrillary tangles (NFTs) and amyloid-rich senile plaques (SPs), the mechanisms leading to the convergence of A68, beta A4, and other proteins in the same AD lesions are unknown. To probe the biological properties of A68 in vivo, and to assess interactions of A68 with endogenous proteins in the rodent brain, we injected A68, dephosphorylated A68 (DEP-A68), and normal adult human tau protein into the hippocampus and neocortex of rats. In marked contrast to DEP-A68 and tau, A68 resisted rapid proteolysis and induced codeposits of three rodent proteins--i.e., beta A4, ubiquitin, and alpha 1-antichymotrypsin (ACT)--that accumulate in AD NFTs and SPs together with A68. These findings suggest that A68 may interact with beta A4, ubiquitin, and ACT in neuronal perikarya as well as in the extracellular space after release of A68 from degenerating neurons. The model system described here will facilitate efforts to elucidate mechanisms leading to the convergence of A68, beta A4, ubiquitin, and ACT in hallmark lesions of AD.

Journal Article
TL;DR: These data may reflect the aberrant induction of neuron-specific gene products in some neoplastic glial cell lines and indicate that some glioma cell lines correspond to transformed bipotential human central nervous system precursors of cells restricted to a neuronal or glial lineage.
Abstract: This report describes the expression of glial and neuronal cytoskeletal proteins and their messenger RNAs (mRNAs) in established cell lines derived from human primitive neuroectodermal tumors (PNETs) and malignant gliomas. Northern blot analyses revealed neurofilament (NF) protein mRNAs in 6 of 7 PNET cell lines but no glial fibrillary acidic protein (GFAP) mRNA. Six of these cell lines contained mRNA for the microtubule-associated protein (MAP) known as MAP1b, whereas MAP2 mRNAs were detected only in 1 of the PNET cell lines. These findings closely paralleled previously published data on the expression of these cytoskeletal proteins in the same group of PNET cell lines. Although GFAP mRNA was detected in only 2 of 5 glioma cell lines, 4 of these cell lines contained mRNAs for the low-molecular-weight (M(r)) NF protein (NF-L). Western blot analysis confirmed the expression of both GFAP and NF-L protein in 2 of the glioma cell lines (U251 MG and U373 MG) that contained GFAP and NF-L mRNAs. Further, double immunofluorescence studies showed that GFAP and NF-L co-localized in the same glioma cells. In contrast, neither the middle- (NF-M) or high- (NF-H) M(r) NF proteins or their mRNAs were detected in any of these glioma cell lines. Finally, MAP1b mRNA was expressed in all 5 glioma cell lines, whereas MAP2 mRNAs were detected in only 3 of the cell lines. This is the first documentation of the expression of both glial-specific and neuron-specific cytoskeletal proteins in human malignant glioma-derived cell lines. These data may reflect the aberrant induction of neuron-specific gene products in some neoplastic glial cell lines. Alternatively, our findings may indicate that some glioma cell lines correspond to transformed bipotential human central nervous system precursors of cells restricted to a neuronal or glial lineage.


Journal Article
TL;DR: In Western blots of immature and mature human cerebral and cerebellar extracts, NST11 did not bind human nestin, but did detect an immunoband with a molecular weight of 220 kd that was detected in medulloblastoma-derived cell lines with a neuron-like phenotype.
Abstract: Nestin is the major intermediate filament protein of embryonic central nervous system (CNS) progenitor cells. To identify proteins involved in early stages of lineage commitment in the developing human CNS we generated monoclonal antibodies to a TrpE-rat nestin fusion protein. This resulted in a monoclonal antibody (designated NST11) that did not recognize authentic human nestin, but did recognize a novel neuron-specific human polypeptide expressed in a subset of embryonic and adult CNS neurons as well as in medulloblastomas. NST11 immunoreactivity was abundant in developing spinal cord motor neurons, but was extinguished in these neurons by 17 weeks gestation. NST11 also labeled Purkinje cells at 17 weeks gestation, but Purkinje cells continued to express the NST11 antigen throughout gestation as well as in the adult cerebellum, and NST11 immunoreactivity was more abundant in Purkinje cells than in any other human CNS neurons. No NST11 immunoreactivity was detected in cells of the adult human peripheral nervous system or in a variety of adult non-neural human tissues. Further, NST11 almost exclusively stained cerebellar medulloblastomas. In Western blots of immature and mature human cerebral and cerebellar extracts, NST11 did not bind human nestin, but did detect an immunoband with a molecular weight of 220 kd. A similar immunoband was detected in medulloblastoma-derived cell lines with a neuron-like phenotype. These findings suggest that the NST11 monoclonal antibody recognizes a novel protein expressed by a subpopulation of immature and mature human CNS neurons, medulloblastomas, and medulloblastoma-derived cell lines.

Journal ArticleDOI
TL;DR: Neuropil threads (NTs) are abnornal processes that are associated with tangle-bearing neurons in gray matter areas of Alzheimer disease (AD) brains as discussed by the authors.
Abstract: Neuropil threads (NTs) are abnornal processes that are associated with tangle-bearing neurons in gray matter areas of Alzheimer disease (AD) brains. Although NTs contain paired helical filaments (PHFs) and share multiple tau epitopes with neurobrillary tangles (NFTs), the relationship between NTs and tangle-bearing neurons is unclear. For this reason, we assessed the continuity of NTs with tangle-bearing and tangle-free neurons. Since astrocytes express low levels of tau and rarely have been shown to contain PHFs, we also examined the relationship of NTs to cortical astrocytes. This was done using histochemical and immunochemical methods in conjunction with confocal laser scanning microscopy to examine NTs in amygdala and entorhinal cortex of seven AD brains. Only a small fraction of NTs (<1%) in 3.5×106 μm3 of amygdala and entorhinal cortex could betraced to local neurons with NFTs or to neurons that did not contain NFTs, and no NTs were continuous with cortical astrocytes. These results indicate that only a very small percentage of NTs in entorhinal cortex and amygdala occur in the most proximal segments of processes that emanate from tangle-bearing or tangle-free neurons. This implies that the majority of NTs reside in the distal parts of dendrites and/or the terminal arborizations of axons or that NTs are discontinuous abnormalities. Taken together, these data suggest that NTs could disrupt local and long distance neuronal circuitry and thereby contribute to the cognitive impairments seen in AD patients.

Patent
29 Oct 1993
TL;DR: In this paper, methods of screening persons for diseases associated with pair helical filaments, including Alzheimer's disease, by detection of τ that has an abnormally phosphorylated serine in the sequence LysSerProVal SEQ ID NO:3 in test samples taken from such persons and test kits useful to perform such methods are disclosed.
Abstract: Substantially purified antibodies, including substantially purified monoclonal antibodies, which are specifically reactive with τ that has an abnormally phosphorylated serine in the sequence LysSerProVal SEQ ID NO:3 are disclosed. Methods of screening persons for diseases associated with pair helical filaments, including Alzheimer's disease, by detection of τ that has an abnormally phosphorylated serine in the sequence LysSerProVal SEQ ID NO:3 in test samples taken from such persons and test kits useful to perform such methods are disclosed.